ADVERTISEMENT

COVID-19: prevention of severe COVID-19 by first intramuscular monoclonals for early outpatient use

Miriam Davis, PhD   |   Clinical Summary   |   07 July 2022
ADVERTISEMENT

Takeaway

  • A single intramuscular injection of 2 monoclonal antibodies, tixagevimab and cilgavimab, reduces the risk of progression to severe COVID-19 or death from any cause by 50.5% when administered in the early outpatient setting.
  • Participants in this phase 3 trial were adults with mild to moderate COVID-19 who were considered...

          

Topic Challenges

left
right